Get the Stockscreener App
62.03
1.93%
-1.22
Pre-market:
61.90
-0.13
-0.21%
Henry Schein Inc stock is traded at $62.03, with a volume of 1.45M.
It is down -1.93% in the last 24 hours and down -9.30% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
See More
Previous Close:
$63.25
Open:
$63.39
24h Volume:
1.45M
Relative Volume:
0.88
Market Cap:
$7.52B
Revenue:
$12.50B
Net Income/Loss:
$314.00M
P/E Ratio:
25.42
EPS:
2.44
Net Cash Flow:
$421.00M
1W Performance:
-3.93%
1M Performance:
-9.30%
6M Performance:
-1.99%
1Y Performance:
-13.55%
1-Day Range:
$61.95
$63.85
1-Week Range:
$61.95
$64.95
52-Week Range:
$60.56
$82.49
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
62.03 | 7.69B | 12.50B | 314.00M | 421.00M | 2.44 |
|
MCK
Mckesson Corporation
|
775.44 | 97.26B | 377.60B | 3.35B | 5.67B | 25.06 |
|
COR
Cencora Inc
|
319.40 | 61.64B | 316.65B | 1.91B | 1.14B | 9.7209 |
|
CAH
Cardinal Health Inc
|
153.27 | 36.63B | 222.58B | 1.57B | 1.85B | 6.4395 |
|
AHG
Akso Health Group Adr
|
1.66 | 911.67M | 2.22M | -5.63M | -1.68M | -0.24 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Is Henry Schein Inc. stock dividend yield sustainableJuly 2025 Decliners & Reliable Volume Spike Trade Alerts - newser.com
TAG Expands Tech With Planmeca Partnership - Dentistry Today
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's Infoods®? Ibs Test in the U.S - MarketScreener
Biomerica (BMRA) Partners with Henry Schein to Expand IBS Test R - GuruFocus
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S. - The Manila Times
Henry Schein and Biomerica enter into marketing services agreement for Biomerica's inFoods IBS Test in the US - MarketScreener
59.6% of treated patients hit FDA abdominal pain endpoint; Biomerica, Henry Schein to market inFoods® in U.S. (ex NY) - Stock Titan
Will Henry Schein Inc. bounce back from current supportEarnings Recap Summary & Safe Investment Capital Preservation Plans - newser.com
CFRA downgrades Henry Schein (HSIC) to a Sell - The Globe and Mail
Analyzing drawdowns of Henry Schein Inc. with statistical toolsEarnings Risk Report & Fast Gain Swing Alerts - newser.com
1,100 Aspen Dental locations to receive Planmeca Viso, ProMax CBCT and intraoral imaging via The Aspen Group - Stock Titan
Building trade automation scripts for Henry Schein Inc.2025 Macro Impact & Free Safe Capital Growth Stock Tips - newser.com
Leerink Partners Adjusts Price Target on Henry Schein to $71 From $72, Maintains Market Perform Rating - MarketScreener
Can Henry Schein Inc. stock hit analyst price targetsPortfolio Return Report & Fast Momentum Stock Entry Tips - newser.com
Understanding Henry Schein Inc.’s price movement2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Can Henry Schein Inc. recover in the next quarter2025 Volatility Report & Proven Capital Preservation Tips - newser.com
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring a 15.93% Potential Upside Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
KKR Builds Stake in Medical-Supply Company, Reaches Deal for Board Seats - MSN
Bank of America Securities Reaffirms Their Buy Rating on Henry Schein (HSIC) - The Globe and Mail
Henry Schein Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Is Henry Schein Inc. stock ready for a breakout2025 Price Action Summary & Detailed Earnings Play Alerts - newser.com
What institutional flow reveals about Henry Schein Inc.2025 Biggest Moves & Daily Stock Trend Watchlist - newser.com
How sentiment analysis helps forecast Henry Schein Inc.Quarterly Profit Summary & Smart Money Movement Alerts - newser.com
Weiss Ratings Reaffirms Hold (C) Rating for Henry Schein (NASDAQ:HSIC) - MarketBeat
3 Reasons to Avoid HSIC and 1 Stock to Buy Instead - The Globe and Mail
Peering Into Henry Schein Inc's Recent Short Interest - Sahm
Henry Schein Inc. stock underperforms Monday when compared to competitors - MarketWatch
Henry Schein subsidiary allegedly compromised by Lynx ransomware - SC Media
July 2026 Options Now Available For Henry Schein (HSIC) - Nasdaq
Tick level data insight on Henry Schein Inc. volatilityWeekly Profit Recap & Real-Time Stock Price Movement Reports - newser.com
Henry Schein to Webcast Fourth Quarter and Full-Year 2024 Conference Call on Tuesday, February 25, 2025, at 8:00 a.m. ET - ADVFN
How to forecast Henry Schein Inc. trends using time seriesMarket Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
Real time breakdown of Henry Schein Inc. stock performanceJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
Henry Schein Announces $400 Million Share Repurchase Plan - ADVFN
What Fibonacci levels say about Henry Schein Inc. rebound2025 Price Action Summary & Reliable Price Breakout Alerts - newser.com
Henry Schein Reports Record Second-Quarter 2021 Financial Results From Continuing Operations - ADVFN
Henry Schein (NASDAQ:HSIC) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Henry Schein subsidiary confirms ransomware attack - Cybernews
Is Henry Schein Inc. stock bottoming outTrade Analysis Summary & Daily Profit Focused Stock Screening - newser.com
Using Ichimoku Cloud for Henry Schein Inc. technicalsMarket Risk Analysis & Consistent Profit Trading Strategies - newser.com
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Henry Schein Inc Stock (HSIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LASKAWY PHILIP A | Director |
Mar 19 '25 |
Sale |
71.04 |
2,604 |
184,999 |
24,805 |
| Connett Bradford C | CEO, NA Distribution Group |
Mar 19 '25 |
Sale |
71.15 |
4,036 |
287,161 |
62,688 |
4.05%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):